P771: PROGNOSTIC CHARACTERISTICS OF PATIENTS WITH MDS WITH ABERRATIONS OF CHROMOSOME 5. DATA FROM THE DÜSSELDORF MDS REGISTRY

• F. Schulz,
• J. Kostova,
• B. Hildebrandt,
• K. Nachtkamp,
• C. Strupp,
• N. Gattermann,
• M. Lübbert,
• S. Blum,
• S. Parmentier,
• K. Götze,
• J. Lipke,
• F. Beier,
• W.-K. Hofmann,
• U. Germing

Affiliations

F. Schulz

1 Department of Hematology, Oncology and Clinical Immunology

J. Kostova

1 Department of Hematology, Oncology and Clinical Immunology

B. Hildebrandt

2 Institute of Human Genetics, University Hospital Düsseldorf, Düsseldorf

K. Nachtkamp

1 Department of Hematology, Oncology and Clinical Immunology

C. Strupp

1 Department of Hematology, Oncology and Clinical Immunology

N. Gattermann

1 Department of Hematology, Oncology and Clinical Immunology

M. Lübbert

3 Department of Medicine I: Hematology, Oncology, and Stem-Cell Transplantation, University Medical Center Freiburg, Freiburg, Germany

S. Blum

4 Department of Hematology and Oncology, Lausanne University Hospital, Lausanne

S. Parmentier

5 Oncology and Hematology, Tumor Center, St. Claraspital, Basel, Switzerland

K. Götze

6 Department of Internal Medicine III, University Hospital Klinikum Rechts der Isar, Munich

J. Lipke

7 Gefos Dortmund, Dortmund

F. Beier

8 Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, University Hospital Aachen, Aachen

W.-K. Hofmann

9 Department of Hematology and Oncology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany

U. Germing

1 Department of Hematology, Oncology and Clinical Immunology